Médecine

Paramédical

Autres domaines


S'abonner

The role of Interleukin 6 inhibitors in therapy of severe COVID-19 - 28/10/20

Doi : 10.1016/j.biopha.2020.110698 
E. Nasonov a, b, c, d , M. Samsonov e,
a V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 
b I.M. Sechenov First Moscow State Medical University, MOH, Moscow, Russia 
c Kashirskoye roadway, 34А, 1115522, Moscow, Russia 
d Trubetskaya str, 8, bdg. 2, 2119991, Moscow, Russia 
e RPharm JSC, Leninsky prospect 111, 11942, Moscow, Russia 

Corresponding author.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Graphical abstract

The role of interleukin 6 inhibitors in therapy of severe COVID-19 Nassonov E, Samsonov M.

RM, Resident macrophages; INF, interferons; NK, natural killers; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor, TNFα, tumor necrosis factor alpha; IP-10, interferon (IFN)γ-induced protein 10; MIP1α, macrophage inflammatory protein; CCL2, CCL7, CXCL9, CXCL10, chemokines.




Le texte complet de cet article est disponible en PDF.

Highlights

Hyperimmune activation plays key role in severe COVID-19.
IL-6 increase associated with poor prognosis and progression.
IL-6 inhibition may improve patient’s conditions.
Treat to target strategy may be applied in COVID-19.

Le texte complet de cet article est disponible en PDF.

Abstract

Cytokine storm syndrome (CSS) is a severe complication of inflammatory immune diseases or treatment of malignancies; it may also appear during the progression of COVID-19. CSS is caused by dysregulation of the synthesis of cytokines, including pro-inflammatory, regulatory, and anti-inflammatory cytokines and chemokines, leading to pathologic activation of innate and adaptive (Th1 and Th17 mediated) immunity. Interleukin-6 (IL-6) plays an important role in the pathogenesis of CSS. The significant role of IL-6 in pathogenesis of COVID-19 was confirmed in a range of studies, which showed that the plasma concentration of IL-6 was increased in patients with severe COVID-19. Currently, IL-6 inhibitor therapeutics are not yet approved for the treatment of COVID-19; however, these medicines, including tocilizumab (TCZ) are used off-label for the treatment of patients with severe COVID-19, including life-threatening conditions. The role of IL-6 in the pathogenesis of CSS during COVID-19 is important however, a number of related issues are not yet clear. These issues include the indications for treatment with IL-6 inhibitors, as well as the estimation of risk associated with the disease, outcomes, treatment options, and adverse drug reactions. The development of personalized immunomodulatory therapy, with respect to the role of cytokines in pathogenesis, requires the studies that aimed to find other relevant therapeutic targets for the treatment of CSS in patients with COVID-19. These therapeutic targets include inhibition of IL-1, IL-6, TNFα, GM-CSF, IFNγ, IL-17, IL-18, and also activation of the complement system.

The challenge of CSS in patients with COVID-19 is identifying the correct scientific targets and developing clinical trials aimed to evaluate the pathogenesis and treat immune-mediated inflammatory diseases (IMIDs). Hopefully, the significant efforts of scientists and physicians across the globe will improve the prognosis in COVID-19 patients and provide useful information on IMIDs required to support the struggle for treating potential viral outbreaks, and treatment of well-known IMIDs.

Le texte complet de cet article est disponible en PDF.

Keywords : COVID-19, interleukin 6, cytokine storm syndrome


Plan


© 2020  The Author(s). Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 131

Article 110698- novembre 2020 Retour au numéro
Article précédent Article précédent
  • Stem cells in natural product and medicinal plant drug discovery—An overview of new screening approaches
  • Erastus Nembu Nembo, Jürgen Hescheler, Filomain Nguemo
| Article suivant Article suivant
  • The emerging role of lncRNAs in chondrocytes from osteoarthritis patients
  • Jiajie Tu, Wei Huang, Weiwei Zhang, Jiawei Mei, Chen Zhu

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.